氨溴索联合头孢哌酮舒巴坦钠治疗老年社区获得性肺炎疗效观察

目的：评价氨溴索联合头孢哌酮舒巴坦钠治疗老年社区获得性肺炎（CAP）的临床疗效。方法：将82例老年CAP患者随机分为治疗组（41例）和对照组（41例）。治疗组给予氨溴索联合头孢哌酮舒巴坦钠治疗,对照组仅给予头孢哌酮舒巴坦钠治疗,治疗10 d后,观察两组临床疗效及不良反应发生情况。结果：治疗组有效率为92.68%,显著高于对照组（70.73%）,差异有统计学意义。两组均未发生药物相关不良反应。结论：氨溴索联合头孢哌酮舒巴坦钠治疗老年CAP疗效显著,用药安全,值得临床推广。     

复方丹参与黄芪注射液治疗冠心病疗效观察

观察复方丹参与黄芪注射液治疗冠心病的临床疗效。随机抽取收治的冠心病患者96例,分为两组,对照组单纯采用复方丹参注射液治疗,研究组则采用复方丹参与黄芪注射液联合治疗,观察两组临床治疗的疗效。治疗后,研究组总有效率为93.75%,明显高于对照组的77.08%,差异有统计学意义(P<0.05);治疗后,两组不良反应较轻,未影响到治疗结果。复方丹参与黄芪注射液联合治疗冠心病的临床疗效较为显著,安全性较高,值得进一步推广应用。     

复方丹参与黄芪注射液治疗冠心病疗效观察

选取74例冠心病患者,随机均分为观察组和对照组。观察组采取复方丹参联合黄芪注射液治疗,对照组采取复方丹参注射液治疗。比较两组患者临床疗效。患者心绞痛改善情况:观察组总有效率为94.59%,对照组为78.38%,两组比较,观察组高于对照组,差异具有统计学意义(P<0.05);患者心电图改善情况:观察组总有效率为94.59%,对照组为67.57%,两组比较,观察组高于对照组,差异具有统计学意义(P<0.05)。复方丹参与黄芪注射液联合使用在治疗冠心病方面疗效显著,值得临床推广。     

左卡尼汀联合前列地尔治疗DN的临床效果分析

目的 观察左卡尼汀联合前列地尔治疗糖尿病肾病(DN)的临床效果,分析对炎症水平及肾功能影响。方法 选取2018年1月～2020年1月我院收治的DN患者300例,随机数字表法分为观察组和对照组各150例。对照组给予前列地尔治疗,观察组在对照组基础上联合左卡尼汀治疗。治疗4周后,评价两组临床疗效,并比较两组血清炎症因子水平:白细胞介素-6(IL-6)、转化生长因子β1(TGF-β1)、单核细胞趋化蛋白(MCP-1),及肾功能指标:血尿素氮(BUN)、血清胱抑素-C(Cys-c)、尿微球蛋白(β2-MG)、24h尿蛋白定量(uPro),记录不良反应发生情况。结果 治疗4周后,观察组总有效率为91.33%,高于对照组的81.33%,差异有统计学意义(P0.05);治疗后,两组血清炎症因子IL-6、TGF-β1、MCP-1水平均低于治疗前,且观察组显著低于对照组,差异均有统计学意义(P0.05);治疗后两组肾功能指标BUN、Cys-c、β2-MG、uPro水平均低于治疗前,且观察组显著低于对照组,差异均有统计学意义(P0.05);观察组不良反应发生率为4.67%,与对照组的3.33%比较差异无统计学意义(P0.05)。结论 左卡尼汀联合前列地尔可提高DN治疗效果,减轻患者炎症反应、改善肾功能,且安全性好。     

头孢哌酮联合舒巴坦治疗肾盂肾炎55例临床分析

目的探讨头孢哌酮联合舒巴坦治疗肾盂肾炎的疗效。方法 98例肾盂肾炎患者按治疗方法分为两组,观察组55例,接受头孢哌酮联合舒巴坦治疗;对照组43例,接受左氧氟沙星治疗。比较两组患者的疗效。结果观察组治疗效果显著优于对照组,两组比较差异有统计学意义(P<0.05)。两组患者均无严重不良反应,其不良反应发生率比较差异无统计学意义(P>0.05)。结论头孢哌酮联合舒巴坦治疗肾盂肾炎具有疗效好、不良反应发生率低等优点,该联合方案可作为肾盂肾炎的常规治疗方案。     

倍他司汀联合复方丹参注射液治疗椎基底动脉供血不足的疗效观察

目的 观察倍他司汀联合复方丹参注射液治疗椎基底动脉供血不足的临床疗效.方法 68例椎基底动脉供血不足患者随机分为治疗组(34例)和对照组(34例).对照组采用复方丹参注射液治疗,治疗组在对照组治疗基础上加用倍他司汀,两组疗程均为2周.治疗结束后比较两组临床疗效和不良反应.结果 治疗组治疗总有效率为88.2%,对照组治疗总有效率为70.6%,两组比较差异有显著性意义(P<0.05);两组治疗期间未见严重不良反应.结论 倍他司汀联合复方丹参注射液治疗椎基底动脉供血不足疗效满意,值得临床推广应用.     

参麦注射液联合注射用环磷腺苷葡胺治疗扩张型心肌病的临床研究

目的分析扩张型心肌病(DCM)应用参麦注射液与注射用环磷腺苷葡胺联合治疗的疗效。方法选取2016年1月～2017年1月我院收治的100例DCM患者,随机分为对照组和观察组,各50例。对照组予以常规综合治疗,观察组在对照组基础上予以参麦注射液联合注射用环磷腺苷葡胺治疗,观察比较两组治疗总有效率、6min步行试验、左室射血分数(LVEF)、每搏量(SV)、左室舒张末期内径(LVEDD)、血清脑钠肽(BNP)水平、转化生长因子-β1(TGF-β1)水平。结果观察组总有效率为90.00%,高于对照组的68.00%,差异有统计学意义(P0.05);治疗后观察组6min步行距离、LVEF、SV高于对照组,LVEDD低于对照组,差异均有统计学意义(P0.05);观察组治疗后血清BNP、TGF-β1水平低于对照组,差异均有统计学意义(P0.05)。结论扩张型心肌病应用参麦注射液与注射用环磷腺苷葡胺联合治疗,可提高患者心功能,改善患者运动耐力,延缓心力衰竭进程,疗效显著。     

痰热清合注射用头孢哌酮钠舒巴坦钠治疗小儿支气管肺炎

目的:探究小儿支气管肺炎采用痰热清注射液联合注射用头孢哌酮钠舒巴坦钠治疗的临床疗效。方法:选取2017年4月～2018年5月我院收治的102例支气管肺炎患儿作为研究对象,根据治疗方案不同分为观察组和对照组,每组51例。对照组在常规治疗的基础上采用注射用头孢哌酮钠舒巴坦钠治疗,观察组在对照组的治疗基础上加用痰热清注射液。比较两组临床疗效、临床症状(咳嗽、发热、肺部湿啰音、气喘)消失时间和不良反应发生情况。结果:观察组总有效率为96.08%,高于对照组的82.35%,差异有统计学意义,P0.05;观察组体温复常、止咳、气喘消失和肺部湿啰音消失时间均较对照组短,差异有统计学意义,P0.05;观察组不良反应发生率为11.76%,与对照组的7.84%相比较,差异无统计学意义,P0.05。结论:痰热清注射液与注射用头孢哌酮钠舒巴坦钠联合治疗小儿支气管肺炎可显著提高临床疗效,快速缓解临床症状,不良反应发生率低。     

复方丙酸氯倍他索软膏联合二氧化碳点阵激光对增生性瘢痕患者VSS评分及复发率的影响

目的探讨复方丙酸氯倍他索软膏联合二氧化碳(CO2)点阵激光治疗增生性瘢痕(HS)患者的临床效果.方法选取2017年7月~2018年6月我院HS患者60例,按随机数字表法分为试验组(n=30)与对照组(n=30),对照组予以复方丙酸氯倍他索软膏,试验组予以复方丙酸氯倍他索软膏联合CO2点阵激光.对比两组疗效、不良反应发生率,记录两组治疗前后温哥华瘢痕量表(VSS)、视觉模拟评分法(VAS)评分及血清血管内皮生长因子(VEGF)、转化生长因子-β(TGF-β)水平;随访1年,对比两组复发率.结果试验组总有效率96.67%(29/30)较对照组80.00%(24/30)高(P<0.05);治疗后,试验组VSS、VAS评分较对照组低(P<0.05);治疗后,试验组血清VEGF、TGF-β水平较对照组低(P<0.05);试验组不良反应发生率10.00%(3/30)与对照组6.67%(2/30)对比无显著差异(P>0.05);试验组复发率3.70%(1/27)较对照组23.81%(5/21)低(P<0.05).结论复方丙酸氯倍他索软膏联合CO2点阵激光治疗HS患者效果显著,可减轻疼痛,下调血清VEGF、TGF-β水平,促使瘢痕恢复,降低复发率,且未明显增加不良反应发生率,值得临床推广应用.     

生长抑素联合复方丹参注射液治疗重症急性胰腺炎的疗效观察

目的探讨生长抑素联合复方丹参注射液治疗重症急性胰腺炎的临床疗效。方法选取2012年1月至2012年12月期间急性胰腺炎患者92例为研究对象,采用对照研究的方法,利用随机数表将其分为对照组和联合用药组,每组46例。两组接受综合疗法,其中对照组加用生长抑素,联合用药组则在对照组的基础上加用复方丹参注射液,分别观察两组的疗效、不良反应情况、血清C反应蛋白(CRP)和细胞间黏附分子-1(ICAM-1)指标,探讨联合用药的的临床应用价值。结果经治疗,联合组和对照组的患者病情均有不同程度的改善,联合用药组的有效率为93.48%,对照组的有效率为88.10%,联合用药组的有效率明显高于对照组,差异有统计学意义(P0.05)。联合用药组出现8例不良反应,不良反应率17.39%;对照组出现7例不良反应,不良反应率15.22%;经卡方检验,两组的不良反应发生率差异无统计学意义(χ2=6.459,P0.05)。治疗后两组各指标均有改善,与治疗前相比,差异有显著性(P0.05)。且联合用药组CRP和ICAM-1在治疗后明显优于对照组,差异有统计学意义(P0.05)。结论生长抑素联合复方丹参注射液治疗重症急性胰腺炎的临床疗效优于单用生长抑素,值得进一步推广应用。     

硝酸甘油联合托拉塞米在高血压危象并发急性肺水肿患者的应用

目的研究硝酸甘油联合托拉塞米治疗高血压危象合并急性肺水肿的效果。方法选取我院收治的高血压危象合并急性肺水肿患者80例作为研究对象。随机分为对照组40例,采用托拉塞米治疗;试验组40例,采用硝酸甘油联合托拉塞米治疗。比较两组患者治疗效果、临床指标改善程度及并发症发生率。结果治疗后对照组患者血压、呼吸频率及氧分压改善程度均低于试验组,且治疗有效率(77.5%)低于试验组(92.5%),差异显著(P0.05);对照组患者并发症发生率(20.0%)高于试验组(7.5%),差异显著(P0.05)。结论采用硝酸甘油联合托拉塞米在治疗高血压危象合并急性肺水肿安全性高,可减少并发症,改善治疗效果,提高患者生活质量。     

Use of crystepin in combination with obsidan in patients with diabetes mellitus with arterial hypertension

Examination included 70 patients with diabetes mellitus in combination with arterial hypertension of different origin (II stage essential hypertension and symptomatic renal arterial hypertension). Crystepin (2-3 tablets per 24 h) in combination with beta-adrenoblocker obsidan (40-80 mg/24 h) was used for treatment. Basic hemodynamic parameters and the state of the renin-aldosterone system were determined. The hemodynamic hypotensive effects in these patients due to the influence of the above therapy are uniform and depend on the form of attendant arterial hypertension. The hypotensive effect of crystepin used in combination with obsidan was more pronounced in patients with diabetes and II stage essential hypertension than that in those with diabetes and renal hypertension. The concentration of aldosterone and renin activity of blood plasma in patients with diabetes and arterial hypertension during treatment with crystepin and obsidan had no regular connection with the hemodynamic parameters.     

Satisfaction with upper-extremity surgery in individuals with tetraplegia

OBJECTIVE: To measure the satisfaction of individuals with tetraplegia with their upper-extremity reconstructive surgery. DESIGN: Survey. SETTING: Two Spinal Cord Injury Model Systems centers. PARTICIPANTS: Sixty-seven individuals with spinal cord injury at the C4 through C8 motor level (107 arms). INTERVENTIONS: Participants had upper-extremity surgery to improve function. The surgical procedures included tendon transfers for elbow extension, wrist extension, hand grasp, and pinch or hand grasp neuroprosthesis. MAIN OUTCOME MEASURE: A survey was mailed to participants, who were asked to respond to statements such as, "If I had it to do over, I would have the hand/arm surgery again," using a 5-level Likert scale (ranging from strongly agree to strongly disagree). RESULTS: Seventy percent of the participants were generally satisfied with the results of their upper-extremity surgery, 77% reported a positive impact on their lives, 68% reported improvements in activities of daily living (ADLs), 66% reported improved independence, 69% reported improvement in occupation, 71% reported improved appearance or neutral, 78% reported their hand worked as well (or neutral) as it did when surgery was first performed, and 86% reported postoperative therapy as being beneficial. CONCLUSIONS: Upper-extremity surgery had a positive impact on life, increased ability to perform ADLs and to be independent, and improved quality of life.     

Observations with Rabenid in patients with locomotor disease

By examining 139 patients suffering from locomotor diseases the author could observe the characteristic accompanying diseases as well as high uric acid level in 40 cases. She analyses the current opinions on hyperuricaemia and reports on her observations with uricosuric and antithrombotic coated Rabenid tablet (RG). She found sulfinpyrazone to be effective and valuable in the examined indication field.     

Satisfaction with medical rehabilitation in patients with orthopedic impairment

OBJECTIVE: To examine patient satisfaction after orthopedic impairment at 80 to 180 days after inpatient rehabilitation. DESIGN: Retrospective design examining records from facilities subscribing to the Uniform Data System for Medical Rehabilitation (UDSmr). SETTING: Information submitted to UDSmr from 1997 to 1998 by 177 hospital and rehabilitation facilities from 40 states. PARTICIPANTS: The sample (N=7781) was 72.63% female and 88.60% non-Hispanic white, with a mean age +/- standard deviation of 73.07+/-11.81 years, and average length of stay (LOS) of 13.84+/-10.48 days. INTERVENTION: Usual rehabilitation care.Main outcome measures Level of satisfaction 80 to 180 days after discharge as well as motor, cognitive, and subscale ratings for the FIM trade mark instrument. Predictor variables included gender, age, English language, marital status, discharge setting, LOS, rehospitalization, FIM gain, and primary payer. RESULTS: A logistic regression model was used to predict patient satisfaction at follow-up. Five statistically significant (P<.05) variables were found and correctly classified 94.9% of the patients. Discharge motor FIM rating, rehospitalization, age, patient's primary language, and discharge setting were associated with increased satisfaction. Discharge motor FIM ratings were significantly associated with increased satisfaction in patients with joint replacements and lower-extremity fractures. CONCLUSION: unctional and demographic variables were identified as predictors of satisfaction in patients with orthopedic impairments.     

Persistence with antimuscarinic therapy in patients with overactive bladder

Overactive bladder (OAB) is a chronic condition, which impacts patients' health and quality of life. The primary symptoms of OAB are distressing and may interfere with work, psychosocial and sexual functioning. OAB also is associated with increased risk of urinary tract infections, fractures from falls, skin infections and depression. Patient's concerns about the effects of incontinence on lifestyle highlight the need to restore continence. The mainstay of treatment is antimuscarinic drug therapy, which may often produce only modest reductions in OAB symptoms and may be accompanied by bothersome adverse effects, leading to poor adherence to prescribed medications. Successful treatment of OAB depends on persistence with the prescribed medication, and efficacy and tolerability are key influencers of persistence. New antimuscarinic agents are now available for treating OAB that significantly improve symptoms of incontinence, urgency and frequency with few adverse effects. An improved efficacy and tolerability profile should result in greater patient satisfaction and persistence with therapy during long-term therapy.